Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 2Unknown 1Terminated 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gynecologic 12Gastrointestinal 5Genitourinary 4Breast 3Tumor-Agnostic 2Other solid neoplasm 2Head & Neck 2CNS 2Thoracic 1Sarcoma 1Dermatologic 1Classical hematology 1

Conditions

Urologic Neoplasms 1Pancreatic Neoplasms 1Neoplasm Metastasis 1Melanoma 1Lung Neoplasms 1Head and Neck Neoplasms 1Esophageal Neoplasms 1Endometrial Neoplasms 1Colonic Neoplasms 1Breast Neoplasms 1

Interventions

pembrolizumab 58Cyclophosphamide 53Ipilimumab 52Nivolumab 44aldesleukin 35Interleukin-2 26fludarabine phosphate 22fludarabine 21Vemurafenib 20Temozolomide 19Radiotherapy 18dabrafenib 15trametinib 12Radiosurgery 11CTLA-4 Antigen 11Filgrastim 10Dacarbazine 10spartalizumab 9cobimetinib 9binimetinib 9atezolizumab 9Biopsy 9poly ICLC 8Paclitaxel 8Antilymphocyte Serum 8encorafenib 7avelumab 7Rituximab 7Introns 7romidepsin 6

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Terminated × niraparib × Dermatologic × Clear all
NCT05169437 2025-10-29

PAVO

Tempus AI

Phase 2 Terminated
22 enrolled 17 charts
BreastDermatologicGastrointestinalGenitourinaryGynecologicHead & NeckThoracic

Breast Neoplasms, Colonic Neoplasms, Esophageal Neoplasms, Head and Neck Neoplasms, Lung Neoplasms, Melanoma, Neoplasm Metastasis, Pancreatic Neoplasms, Urologic Neoplasms, Endometrial Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡